Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter



: Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A

Publisher: AMER ASSOC CANCER RESEARCH

: 2009

: Clinical Cancer Research

: CLINICAL CANCER RESEARCH

: CLIN CANCER RES

: 15

: 17

: 5396

: 5403

: 8

: 1078-0432

DOI: https://doi.org/10.1158/1078-0432.CCR-08-2571


Purpose: Oncolytic adenoviruses are promising tools for cancer therapy. Although several clinical reports have indicated both safety and promising antitumor capabilities for these viruses, there are only a few examples of complete tumor eradication. Thus, the antitumor efficacy of oncolytic adenoviruses needs to be improved. One potentially useful approach is combination with radiotherapy.Experimental Design: To target systemically administered radioiodide to tumors, we created Ad5/3-Delta 24-human sodium iodide symporter (hNIS), a Rb-p16 pathway selective infectivity enhanced oncolytic adenovirus encoding hNIS.Results: Ad5/3-Delta 24-hNIS replication effectively killed prostate cancer cells in vitro and in vivo. Also, the virus-mediated radioiodide uptake into prostate cancer cells in vitro and into tumors in vivo. Furthermore, Ad5/3-Delta 24-hNIS with radioiodide was significantly more effective than virus alone in mice with prostate cancer xenografts.Conclusions: These results suggest that oncolytic adenovirus-mediated targeted radiotherapy might be a potentially useful option for enhancing the efficacy or adenoviral virotherapy. (Clin Cancer Res 2009;15(17):5396-403)



Last updated on 2024-26-11 at 20:09